Renal-Protective Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone in ob/ob Mice

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Obesity-related glomerulopathy (ORG) is a significant complication of obesity.
• Peroxisome proliferator-activated receptor-γ (PPARγ) agonists, like pioglitazone, are investigated for therapeutic potential.
• Murine models (ob/ob mice) are utilized to study ORG and its treatment.

Purpose of the Study:

• To investigate the therapeutic effects of pioglitazone on obesity-related glomerulopathy (ORG) in ob/ob mice.
• To evaluate the impact of pioglitazone on metabolic parameters and kidney function.
• To examine the molecular mechanisms underlying pioglitazone's effects on renal histology and protein expression.

Main Methods:

• Utilized three groups of mice: wild-type C57BL/6, ob/ob, and pioglitazone-treated ob/ob mice.
• Monitored body mass, blood glucose, serum adiponectin (ADP), and urine microalbumin (mALB).
• Performed renal histology (light and electron microscopy) and assessed expression of WT1, ZO-1, AMPK, and NOX-4 via immunohistochemistry and Western blot.

Main Results:

• Pioglitazone treatment prevented the decrease in serum adiponectin and the rise in urine microalbumin observed in ob/ob mice.
• Histological analysis showed pioglitazone ameliorated glomerulomegaly, mesangial proliferation, glomerulosclerosis, and podocyte foot process fusion.
• Pioglitazone normalized kidney index, glomerular diameter, and reversed altered expression of WT1, ZO-1, AMPK, and NOX-4 in ob/ob mice.

Conclusions:

• Pioglitazone, a PPARγ agonist, demonstrates preventative effects against obesity-related glomerulopathy in a murine model.
• The therapeutic benefits of pioglitazone likely involve the reduction of oxidative stress.
• Pioglitazone shows promise as a treatment for ORG, potentially by modulating key cellular pathways.